We are utilizing our nitric oxide expertise and proprietary position to develop product candidates for a variety of additional medical conditions. The following table highlights those classes of nitric oxide-enhancing medicines where we have created, or are seeking to create, intellectual property rights and where we believe we may offer a clinical benefit compared to existing FDA-approved medicines. Our efforts in these areas primarily consist of discovery-stage research primarily directed to establishing our intellectual property position.
| Product Candidate and Therapeutic Area |
Potential Clinical Benefits |
| Nitric Oxide-Enhancing NSAIDs |
| • |
Pain, inflammation, cancer, and central nervous system diseases |
• |
Improved gastrointestinal tolerance; accelerated ulcer healing; reduced kidney damage and hypertension |
| Nitric Oxide-Enhancing PDE Inhibitors |
| • |
Pain, inflammation, cancer, and central nervous system diseases |
• |
Anti-nociceptive, anti-inflammatory, enhanced efficacy, fewer side effects |
| • |
Asthma
|
• |
Increased airway circulation; reduced lung inflammation and decreased sensitivity to airborne allergens |
| • |
Male erectile dysfunction |
• |
Increased response rate; rapid onset of action |
| • |
Pulmonary hypertension |
• |
Increased efficacy; longer duration of action |
| • |
Chronic obstructive airway disease |
• |
Increased airway circulation |
| Nitric Oxide-Enhancing Steroids |
| • |
Allergy and Asthma |
• |
Faster onset of action; increased airway circulation |
| • |
Dermatology |
• |
Faster onset of action; increased efficacy |
| Nitric Oxide-Enhancing Gastrointestinal Protectants |
| • |
Peptic ulcer |
• |
Improved efficacy; faster onset of action |
| Nitric Oxide-Enhancing Arginines |
| • |
Kidney failure |
• |
Improved sodium and water balances |
| Nitric Oxide-Enhancing Antibiotics |
| • |
Cystic Fibrosis |
• |
Improved antibacterial activity, increased mucus production |
